These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24463621)

  • 1. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.
    Uaesoontrachoon K; Quinn JL; Tatem KS; Van Der Meulen JH; Yu Q; Phadke A; Miller BK; Gordish-Dressman H; Ongini E; Miglietta D; Nagaraju K
    Hum Mol Genet; 2014 Jun; 23(12):3239-49. PubMed ID: 24463621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.
    Miglietta D; De Palma C; Sciorati C; Vergani B; Pisa V; Villa A; Ongini E; Clementi E
    Orphanet J Rare Dis; 2015 Aug; 10():101. PubMed ID: 26296873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy.
    Thomas GD; Ye J; De Nardi C; Monopoli A; Ongini E; Victor RG
    PLoS One; 2012; 7(11):e49350. PubMed ID: 23139842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly oral prednisolone improves survival and strength in male mdx mice.
    Keeling RM; Golumbek PT; Streif EM; Connolly AM
    Muscle Nerve; 2007 Jan; 35(1):43-8. PubMed ID: 16969833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
    Mele A; Mantuano P; De Bellis M; Rana F; Sanarica F; Conte E; Morgese MG; Bove M; Rolland JF; Capogrosso RF; Pierno S; Camerino GM; Trabace L; De Luca A
    Transl Res; 2019 Feb; 204():82-99. PubMed ID: 30347179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.
    Capogrosso RF; Mantuano P; Uaesoontrachoon K; Cozzoli A; Giustino A; Dow T; Srinivassane S; Filipovic M; Bell C; Vandermeulen J; Massari AM; De Bellis M; Conte E; Pierno S; Camerino GM; Liantonio A; Nagaraju K; De Luca A
    FASEB J; 2018 Feb; 32(2):1025-1043. PubMed ID: 29097503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
    Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
    J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
    Consalvi S; Mozzetta C; Bettica P; Germani M; Fiorentini F; Del Bene F; Rocchetti M; Leoni F; Monzani V; Mascagni P; Puri PL; Saccone V
    Mol Med; 2013 May; 19(1):79-87. PubMed ID: 23552722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of PDE5 inhibition on dystrophic muscle following an acute bout of downhill running and endurance training.
    Batra A; Vohra RS; Chrzanowski SM; Hammers DW; Lott DJ; Vandenborne K; Walter GA; Forbes SC
    J Appl Physiol (1985); 2019 Jun; 126(6):1737-1745. PubMed ID: 30946638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice.
    Sali A; Many GM; Gordish-Dressman H; van der Meulen JH; Phadke A; Spurney CF; Cnaan A; Hoffman EP; Nagaraju K
    PLoS One; 2013; 8(7):e66617. PubMed ID: 23843959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.
    Spurney CF; Sali A; Guerron AD; Iantorno M; Yu Q; Gordish-Dressman H; Rayavarapu S; van der Meulen J; Hoffman EP; Nagaraju K
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):87-95. PubMed ID: 21304057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.
    Li H; Mittal A; Makonchuk DY; Bhatnagar S; Kumar A
    Hum Mol Genet; 2009 Jul; 18(14):2584-98. PubMed ID: 19401296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
    Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
    Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.
    Spurney CF; Guerron AD; Yu Q; Sali A; van der Meulen JH; Hoffman EP; Nagaraju K
    BMC Cardiovasc Disord; 2011 May; 11():20. PubMed ID: 21575230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.